Bristol-Myers presents data on daclatasvir at Liver Meeting
Seeking Alpha - at Seeking Alpha - Sat Apr 25, 6:30PM CDT
GILD: 103.69 (-1.52), BMY: 65.80 (-0.20)
Preliminary data show 100% SVR4 for Viekirax + Exviera
Seeking Alpha - at Seeking Alpha - Sat Apr 25, 4:48PM CDT
GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82), BMY: 65.80 (-0.20), ENTA: 37.14 (+0.56)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Apr 24, 7:21PM CDT
There are still plenty of companies doing well this quarter and investors need to take advantage of the opportunities when they see them, Cramer says.
GRUB: 46.00 (-0.25), XOM: 86.97 (-0.57), KRFT: 87.57 (-0.81), UPS: 98.10 (-0.12), SBUX: 51.84 (+2.41), SAVE: 77.42 (+0.43), IBM: 169.78 (-0.46), GOOGL: 573.66 (+16.20), SIX: 51.08 (+1.20), TMUS: 34.31 (-0.13), TWTR: 50.82 (-0.59), CBSH: 42.67 (-0.10), MSFT: 47.87 (+4.53), AAPL: 130.28 (+0.61), WFM: 49.63 (+1.38), AMZN: 445.10 (+55.11), FTR: 7.03 (-0.04), SEAS: 21.49 (+0.35), COLM: 62.84 (+0.73), FCAU: 16.19 (+0.11), BMY: 65.80 (-0.20), MAR: 81.84 (+0.49), CLB: 124.69 (-0.63), NFLX: 558.40 (-0.66), RDS.A: 62.76 (-0.20), QLIK: 35.30 (+1.65), CVS: 101.58 (+0.70), CVX: 109.87 (-0.10)
Final Glance: Pharmaceuticals companies
AP - Fri Apr 24, 7:08PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 101.08 (+0.62), BAX: 71.14 (-0.37), PFE: 35.27 (-0.09), BMY: 65.80 (-0.20)
Midday Glance: Pharmaceuticals companies
AP - Fri Apr 24, 12:36PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 101.08 (+0.62), BAX: 71.14 (-0.37), PFE: 35.27 (-0.09), BMY: 65.80 (-0.20)
Early Glance: Pharmaceuticals companies
AP - Fri Apr 24, 9:55AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 101.08 (+0.62), BAX: 71.14 (-0.37), PFE: 35.27 (-0.09), BMY: 65.80 (-0.20)
Bristol-Myers may be mulling bid for Celgene
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 9:27AM CDT
BMY: 65.80 (-0.20), CELG: 118.71 (+2.62)
European Ad Comm backs Bristol-Myers' Opdivo for melanoma
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 9:14AM CDT
BMY: 65.80 (-0.20)
Merck's HCV combo shows cure rates of 60 - 100% in three genotypes
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 8:05AM CDT
JNJ: 101.08 (+0.62), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82), BMY: 65.80 (-0.20)
Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients
Business Wire - Fri Apr 24, 6:46AM CDT
--Opinion based on superior survival benefit demonstrated from CheckMate -066 trial in first-line patients and improved response rate in CheckMate -037 study in previously treated patients
BMY: 65.80 (-0.20)
Will Biogen's (BIIB) Earnings Streak Continue in 1Q? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Apr 23, 3:57PM CDT
Investor focus this quarter will remain on the performance of Biogen's (BIIB) oral MS treatment, Tecfidera.
BIIB: 401.71 (-28.57), UTHR: 186.69 (-1.87), TEVA: 64.41 (+1.16), BMY: 65.80 (-0.20)
A Discussion Of Amgen's Q1 Results, With Updates On Its Pipeline
DoctoRx - at Seeking Alpha - Wed Apr 22, 8:28AM CDT
PFE: 35.27 (-0.09), AMGN: 167.91 (-1.26), LLY: 71.58 (-0.82), BMY: 65.80 (-0.20), SNY: 51.75 (-0.01), REGN: 480.09 (+0.01), HSP: 87.61 (-0.05), CELG: 118.71 (+2.62)
Is Immuno-Oncology the Best Area of Biotech to Invest in Right Now?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 22, 7:11AM CDT
Biotechnology is rapidly giving rise to ground-breaking new medicines that are dramatically changing the outlook for devastating diseases such as hepatitis C, malaria, and, perhaps most astoundingly, cancer. This innovation boom has gone hand in hand...
AGEN: 7.12 (+0.75), ADXS: 23.34 (-0.27), PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), BMY: 65.80 (-0.20), FPRX: 24.20 (-0.26)
Clopidogrel Bisulfate Market 2015-2020 Research Reviews
PR Newswire - Wed Apr 22, 7:00AM CDT
DeepResearchReports.com have "2015 Market Report on Global Clopidogrel Bisulfate Industry" added to its research database. The report spread across 159 pages and available for ready purchase priced at the single user pdf (USD 2600).
BMY: 65.80 (-0.20)
Healthcare's Health Scanner: Complementary Research on Pfizer, Mylan, Teva Pharmaceutical, Bristol-Myers Squibb, and Merck & Company
PR Newswire - Wed Apr 22, 7:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.
MRK: 57.60 (+0.09), PFE: 35.27 (-0.09), MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16), BMY: 65.80 (-0.20)
Exelixis on Path to Beat Estimates; Analyst Brief Issued by BrokerBank Securities, Inc.
PR Newswire - Wed Apr 22, 6:00AM CDT
Exelixis, Inc. (NASDAQ: EXEL) a San Francisco based biotechnology company is set to announce its latest earnings results on April 30, 2015. With recent revisions of earnings estimates, investors are watching to see this darling continue to perform. Exelixis has appreciated significantly since the start of 2015 and growth is expected to continue. Seeing favorable results on its leading compound from the FDA drives the idea of future growth potential.
MRK: 57.60 (+0.09), BMY: 65.80 (-0.20), EXEL: 3.08 (-0.02)
Seattle Genetics' Adcetris Under Review for New Indication - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 5:07PM CDT
Seattle Genetics, Inc.'s (SGEN) supplemental BLA for Adcetris has been accepted by the FDA for priority review as consolidation therapy in the post-transplant setting.
SGEN: 37.14 (-0.36), SHPG: 255.11 (-0.26), HZNP: 31.75 (+0.97), BMY: 65.80 (-0.20)